These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27920543)

  • 21. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
    Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
    J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presentation and complications associated with cirrhosis of the liver.
    Poordad FF
    Curr Med Res Opin; 2015 May; 31(5):925-37. PubMed ID: 25697811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intestinal dysfunction in liver cirrhosis: Its role in spontaneous bacterial peritonitis.
    Ramachandran A; Balasubramanian KA
    J Gastroenterol Hepatol; 2001 Jun; 16(6):607-12. PubMed ID: 11422611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?
    Fukui H
    Inflamm Intest Dis; 2016 Oct; 1(3):135-145. PubMed ID: 29922669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.
    Augustyn M; Grys I; Kukla M
    Clin Exp Hepatol; 2019 Mar; 5(1):1-10. PubMed ID: 30915401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.
    Ilan Y
    World J Gastroenterol; 2012 Jun; 18(21):2609-18. PubMed ID: 22690069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbiome and bacterial translocation in cirrhosis.
    Gómez-Hurtado I; Such J; Francés R
    Gastroenterol Hepatol; 2016 Dec; 39(10):687-696. PubMed ID: 26775042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.
    Muñoz L; Borrero MJ; Úbeda M; Conde E; Del Campo R; Rodríguez-Serrano M; Lario M; Sánchez-Díaz AM; Pastor O; Díaz D; García-Bermejo L; Monserrat J; Álvarez-Mon M; Albillos A
    Hepatology; 2019 Sep; 70(3):925-938. PubMed ID: 30414342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.
    Riva A; Gray EH; Azarian S; Zamalloa A; McPhail MJW; Vincent RP; Williams R; Chokshi S; Patel VC; Edwards LA
    JHEP Rep; 2020 Dec; 2(6):100151. PubMed ID: 32838247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment.
    Piotrowski D; Boroń-Kaczmarska A
    Adv Med Sci; 2017 Sep; 62(2):345-356. PubMed ID: 28514703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options.
    Twardowska A; Makaro A; Binienda A; Fichna J; Salaga M
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implication of the intestinal microbiome in complications of cirrhosis.
    Bhat M; Arendt BM; Bhat V; Renner EL; Humar A; Allard JP
    World J Hepatol; 2016 Sep; 8(27):1128-1136. PubMed ID: 27721918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.
    Fukui H
    J Clin Transl Hepatol; 2017 Sep; 5(3):249-260. PubMed ID: 28936406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington's disease.
    Stan TL; Soylu-Kucharz R; Burleigh S; Prykhodko O; Cao L; Franke N; Sjögren M; Haikal C; Hållenius F; Björkqvist M
    Sci Rep; 2020 Oct; 10(1):18270. PubMed ID: 33106549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the Relationship between Liver Disease, Bacterial Translocation, and Dysbiosis: Unveiling the Gut-Liver Axis.
    Juanola O; Francés R; Caparrós E
    Visc Med; 2024 Feb; 40(1):12-19. PubMed ID: 38312368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidative Mechanisms and Cardiovascular Abnormalities of Cirrhosis and Portal Hypertension.
    Liu H; Nguyen HH; Hwang SY; Lee SS
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods to determine intestinal permeability and bacterial translocation during liver disease.
    Wang L; Llorente C; Hartmann P; Yang AM; Chen P; Schnabl B
    J Immunol Methods; 2015 Jun; 421():44-53. PubMed ID: 25595554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.